May 24, 2017 07:07 AM EDT

Zai Lab CEO Samantha Du is raising a $150M biotech fund

John Carroll

Editor & Founder

Shanghai-based Zai Lab isn’t just working on its own pipeline of drugs anymore. CEO Samantha Du, a Pfizer vet who helped start Hutchison MediPharma, has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Zai Lab CEO Samantha Du is raising a $150M biotech fund

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Zai Lab CEO Saman­tha Du is rais­ing a $150M biotech fund

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Zai Lab CEO Samantha Du is raising a $150M biotech fund

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Outlook's shares crash as wet AMD drug flunks Phase 3 test